
|Articles|October 24, 2012
VMA treatment approved
The FDA has approved ocriplasmin (Jetrea, ThromboGenics) for the treatment of symptomatic vitreomacular adhesion (VMA).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement




























